Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd[®] has demonstrated significant effect in a subgroup which covers about half of all type 1 diabetes patients. In connection to this, CEO Ulf Hannelius together with the trial’s  Coordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET. The presentation is hosted by News Agency Direkt and Direkt Studios and can be watched at https://youtu.be/UH6sr8WIbaQ   About Diamyd Medical Diamyd Medical develops